These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 15889986)

  • 1. Paving the way for the introduction of new vaccines into developing countries.
    Chabalgoity JA
    Expert Rev Vaccines; 2005 Apr; 4(2):147-50. PubMed ID: 15889986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translational research to assist policy decisions about introducing new vaccines in developing countries.
    Clemens JD; Jodar L
    J Health Popul Nutr; 2004 Sep; 22(3):223-31. PubMed ID: 15609774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rotavirus vaccines: targeting the developing world.
    Glass RI; Bresee JS; Turcios R; Fischer TK; Parashar UD; Steele AD
    J Infect Dis; 2005 Sep; 192 Suppl 1():S160-6. PubMed ID: 16088799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.
    Jadhav S; Datla M; Kreeftenberg H; Hendriks J
    Vaccine; 2008 Mar; 26(13):1611-5. PubMed ID: 18294742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global perspectives on vaccine financing.
    Berman S; Giffin RB
    Expert Rev Vaccines; 2004 Oct; 3(5):557-62. PubMed ID: 15485335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chapter 26: Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries.
    Batson A; Meheus F; Brooke S
    Vaccine; 2006 Aug; 24 Suppl 3():S3/219-25. PubMed ID: 16950010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PneumoADIP: an example of translational research to accelerate pneumococcal vaccination in developing countries.
    Levine OS; Cherian T; Shah R; Batson A
    J Health Popul Nutr; 2004 Sep; 22(3):268-74. PubMed ID: 15609779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GAVI and the Vaccine Fund--a boon for immunization in the developing world.
    Balaji KA
    Indian J Public Health; 2004; 48(2):45-8. PubMed ID: 15709583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral vaccines: new needs, new possibilities.
    Aziz MA; Midha S; Waheed SM; Bhatnagar R
    Bioessays; 2007 Jun; 29(6):591-604. PubMed ID: 17508389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breaking new ground--are changes in immunization services needed for the introduction of future HIV/AIDS vaccines and other new vaccines targeted at adolescents?
    Clements CJ; Abdool-Karim Q; Chang ML; Nkowane B; Esparza J
    Vaccine; 2004 Jul; 22(21-22):2822-6. PubMed ID: 15246617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The introduction of new vaccines into developing countries. IV: Global Access Strategies.
    Mahoney RT; Krattiger A; Clemens JD; Curtiss R
    Vaccine; 2007 May; 25(20):4003-11. PubMed ID: 17363119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Policy analysis: an essential research tool for the introduction of vaccines in developing countries.
    Mahoney R
    J Health Popul Nutr; 2004 Sep; 22(3):331-7. PubMed ID: 15609786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of emerging manufacturers in access to innovative vaccines of public health importance.
    Milstien JB; Kaddar M
    Vaccine; 2010 Feb; 28(9):2115-21. PubMed ID: 20044054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?
    Lydon P; Levine R; Makinen M; Brenzel L; Mitchell V; Milstien JB; Kamara L; Landry S
    Vaccine; 2008 Dec; 26(51):6706-16. PubMed ID: 18952134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human vaccine research and development: an overview.
    Kieny MP; Girard MP
    Vaccine; 2005 Dec; 23(50):5705-7. PubMed ID: 16182415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Introduction of vaccination against human papillomavirus in developing countries: update and perspectives].
    Hessel L
    Med Trop (Mars); 2009 Aug; 69(4):323-6. PubMed ID: 19725378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of globalization on vaccine development and availability.
    Milstien JB; Kaddar M; Kieny MP
    Health Aff (Millwood); 2006; 25(4):1061-9. PubMed ID: 16835187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rotavirus vaccines for infants in developing countries in Africa and Asia: considerations from a world health organization-sponsored consultation.
    Steele AD; Patel M; Parashar UD; Victor JC; Aguado T; Neuzil KM
    J Infect Dis; 2009 Nov; 200 Suppl 1():S63-9. PubMed ID: 19817616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.